PharmaCyte Biotech, Inc. lost $2.77 per diluted share in fiscal year 2026. This represents a decrease of 186.8% from the prior fiscal year. Over the trailing 12 months, Q2 FY2026 through Q1 FY2027, the same line adds up to a loss of $2.31 per diluted share. The table below carries 15 fiscal years, from 2012 to 2026, and the quarters PharmaCyte Biotech, Inc. has filed alongside them.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
What was PharmaCyte Biotech, Inc.'s diluted earnings per share in fiscal year 2026?
PharmaCyte Biotech, Inc. lost $2.77 per diluted share in fiscal year 2026.
How fast is PharmaCyte Biotech, Inc.'s diluted earnings per share growing?
PharmaCyte Biotech, Inc. (PMCB) diluted earnings per share fell by 186.8% year over year, from $3.19 to -$2.77 in fiscal year 2026.
What is PharmaCyte Biotech, Inc.'s diluted earnings per share over the last twelve months?
PharmaCyte Biotech, Inc. (PMCB) reported a loss of $2.31 per diluted share over the trailing 12 months, Q2 FY2026 through Q1 FY2027, summed from the four most recent quarterly filings.
What was PharmaCyte Biotech, Inc.'s diluted earnings per share in the most recent quarter?
PharmaCyte Biotech, Inc. (PMCB) reported -$0.54 in diluted earnings per share in Q1 2027. This represents an increase of 56.1% from the same quarter a year earlier.
What does diluted earnings per share mean on a financial statement?
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what PharmaCyte Biotech, Inc. (PMCB) reported on that line in every period on record.
